NLM Digital Collections

Search

Start Over Subjects Antirheumatic Agents -- adverse effects ✖Remove constraint Subjects: Antirheumatic Agents -- adverse effects Subjects Randomized Controlled Trials as Topic ✖Remove constraint Subjects: Randomized Controlled Trials as Topic

1. Targeted immune modulators for rheumatoid arthritis: effectiveness and value : evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 7, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Arthritis, Rheumatoid -- immunology
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Drug Therapy, Combination
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Janus Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Tumor Necrosis Factors -- antagonists & inhibitors
Humans
United States

2. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 6, 2017
Subject(s):
Comparative Effectiveness Research
Multiple Sclerosis, Chronic Progressive -- drug therapy
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- economics
Antirheumatic Agents -- therapeutic use
Benchmarking
Cost-Benefit Analysis
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- economics
Immunosuppressive Agents -- therapeutic use
Insurance Coverage
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States